Fig. 1 | Microbial Cell Factories

Fig. 1

From: Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study

Fig. 1

Clinical response to FMT monotherapy (FMT group) and routine therapy (control group) after two weeks of treatment. a Abdominal pain score of patients with active UC at baseline and 2 weeks after treatment. In the FMT group, the value was 4.5 ± 2.2 at baseline and 0.9 ± 1.6 after FMT monotherapy (n = 10). In the control group, the values were 4.9 ± 2.1 at baseline and 1.8 ± 1.3 after routine therapy (n = 10). Compared with that observed in pretreatment, abdominal pain significantly improved after FMT treatment and routine therapy (* P = 0.000). b Diarrheal frequency of patients with active UC at baseline and 2 weeks after FMT monotherapy. In the FMT group, the value was 8.8 ± 3.8 at baseline and 2.5 ± 2.7 after FMT monotherapy (n = 10). In the control group, the values were 7.8 ± 3.1 at baseline and 3.3 ± 1.0 after routine therapy (n = 10). Compared with that observed in pretreatment, diarrheal frequency significantly improved after FMT treatment and routine therapy (# P = 0.000)

Back to article page